Here’s what you should know:
1. The candidate was tested on “three subcutaneous or orthotopic liver cancer xenograft models treated with the active cytotoxic compound maytansine conjugated with Midatech’s gold nanoparticle technology.”
2. The candidate had anti-tumor properties in all models. In some models tumor growth was reduced more than six-fold. However, the mean reduction throughout all three models was three-fold.
3. MTD119 targets advanced hepatocellular carcinoma.
4. Midatech is beginning its formal investigation process now. The company expects to submit an application to the FDA for its first clinical studies in 2018.
More articles on gastroenterology:
Eisai submits liver cancer treatment application to FDA — 5 notes
GI center to know: Illinois Gastroenterology Institute
Capital Digestive Care adds 2 physicians & more: 5 GI practices in the news
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.
